Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 16 citing articles:

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Advancements and Challenges in the Treatment of AML
Yasmin Abaza, Christine M. McMahon, Jacqueline S. Garcia
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 7
Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy
A Schupbach, Dilara Akhoundova, Ulrike Bacher, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1138-1138
Open Access
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Deleted Journal (2024) Vol. 1, Iss. 3, pp. 100017-100017
Open Access | Times Cited: 3
Acute myeloid leukemia management and research in 2025
Hagop M. Kantarjian, Courtney D. DiNardo, Tapan M. Kadia, et al.
CA A Cancer Journal for Clinicians (2024)
Open Access | Times Cited: 3
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1790-1801
Closed Access | Times Cited: 2
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients
Francis LeBlanc, Erin H. Breese, Karen Burns, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 1055-1066
Open Access | Times Cited: 2
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Expert Review of Hematology (2024) Vol. 17, Iss. 10, pp. 723-739
Closed Access | Times Cited: 2
Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 515-518
Open Access | Times Cited: 1
Less is More: An Analysis of Venetoclax and Hypomethylating Agent Post-Induction Treatment Modifications in AML
Stéphanie Boisclair, Edward Zhou, Phyu Thin Naing, et al.
Leukemia Research (2024) Vol. 143, pp. 107545-107545
Closed Access | Times Cited: 1
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML
Dahniel Sastow, Hannah Levavi, Nicole Wagner, et al.
Blood Reviews (2024) Vol. 68, pp. 101238-101238
Closed Access | Times Cited: 1
Toward an improved understanding of hypomethylating agent and venetoclax therapies
Courtney D. DiNardo
American Journal of Hematology (2023) Vol. 99, Iss. 2, pp. 152-154
Closed Access | Times Cited: 2
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Maximilian Fleischmann, Madlen Jentzsch, Annamaria Brioli, et al.
Annals of Hematology (2024)
Open Access
Short-term Group Venetoclax Combined with Azacitidine for Treating Newly Diagnosed Elderly Acute Myeloid Leukemia: A Retrospective Study
Zhuruohan Yu, Shuangyue Li, Renzhi Pei, et al.
(2024)
Closed Access
Page 1

Scroll to top